Novo Nordisk: FDA posts briefing materials prior to Advisory Committee meeting for semaglutide
(WorldNews Denmark)

FDA posts briefing materials prior to Advisory Committee meeting for semaglutide Bagsværd, Denmark, 16 October 2017 - Novo Nordisk today announced that the US Food and Drug Administration (FDA) has published the briefing documents ahead of the Advisory Committee meeting to discuss the New Drug Application (NDA) for approval of semaglutide, a once-weekly analogue of human glucagon-like peptide-1 (GLP-1) for the treatment of type 2 diabetes in adults. The meeting takes place on 18 October 2017. The briefing documents from Novo Nordisk and the...